March 13th 2025
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
USPSTF: Data on vitamins for cancer prevention lacking
November 18th 2013Data are lacking to recommend for or against the use of vitamins, minerals, and multivitamin supplements for the prevention of cancer and cardiovascular disease, according to a new U.S. Preventive Services Task Force draft recommendation statement.
Body composition unchanged after advanced prostate cancer treatment
November 18th 2013No differences in body composition were found among metastatic castration-resistant prostate cancer patients taking abiraterone acetate (ZYTIGA), enzalutamide (Xtandi), or placebo who were treated as part of two clinical trials.
New Urology Products and Services November 2013
October 29th 2013The latest products and services from SuperSonic Imagine, Auxilium Pharmaceuticals, VIVUS, the Centers for Medicare & Medicaid Services, Innovus Pharmaceuticals, Buffalo Filter, KRS Global Biotechnology, Demos Health, and Ethicon Endo-Surgery.
Prostate cancer agent meets key endpoints in pre-chemo setting
October 28th 2013A phase III trial of enzalutamide (Xtandi) in chemotherapy-naïve patients with advanced prostate cancer has met both of its primary endpoints in an interim analysis, and the trial will be stopped early due to the drug’s benefit.
Intensity-modulated radiation therapy study reignites urologist self-referral controversy
October 25th 2013The publication of data in the New England Journal of Medicine (2013; 369:1629-37) showing an increase in intensity-modulated radiation therapy utilization among self-referring urologists has reignited the self-referral controversy.
PSA testing still common in men >75 years
October 21st 2013Many physicians continue to administer the PSA test to even their oldest patients despite the fact that no medical organization recommends routine prostate cancer screening in men older than 75 years of age, according to recently published research.
Prognostic model predicts survival in advanced prostate cancer
October 21st 2013Researchers at the Duke Cancer Institute in Durham, NC say they have developed a tool to forecast the potential survival of individual prostate cancer patients, enabling physicians to better assess whether to try additional rounds of treatment or seek clinical trials.
Primary androgen deprivation therapy linked to lower survival in American men
October 18th 2013Primary androgen deprivation therapy for localized prostate cancer is associated with significantly better survival outcomes in a Japanese cohort compared with an American population, according to a recent study.
Sipuleucel-T viable during abiraterone treatment
October 8th 2013Data from a phase II study suggest that the potency of sipuleucel-T (Provenge) and immunologic prime-boost responses are maintained when the immunotherapy is administered concurrently or sequentially with abiraterone acetate (ZYTIGA) plus prednisone.
Short-term as good as long-term hormonal therapy
September 30th 2013Short-term hormone therapy appears to produce outcomes that are as favorable as those for long-term therapy in men with intermediate-risk prostate cancer, according to the results of two studies from the Radiation Therapy Oncology Group.
Environmental toxins harm fertility, prostate health
September 30th 2013Toxic chemicals in the environment harm our ability to reproduce and are associated with poor semen quality and prostate cancer, among other long-term health problems, according to the American College of Obstetricians and Gynecologists and the American Society for Reproductive Medicine.
ASTRO, AAFP Choosing Wisely lists target prostate cancer, urinary tract infection
September 30th 2013The American Society for Radiation Oncology and the American Academy of Family Physicians have both released recommendations on the diagnosis and treatment of prostate cancer as part of the Choosing Wisely campaign.
Incidence of non-osseous metastatic prostate cancer on the rise
September 19th 2013New therapies that are extending survival of men with metastatic castration-resistant prostate cancer may also be contributing to an increasing trend for the development of non-osseous metastatic disease in these patients, according to a recent study.
LUGPA position aims to clarify prostate cancer screening
September 16th 2013In an attempt to clarify what it calls conflicting guideline statements on prostate cancer screening from various organizations, the Large Urology Group Practice Association has issued its own position on the use of the PSA test as a screening tool.
Patient sues after radiation therapy damages bladder
September 13th 2013In this case, the patient tried to keep the observing urologist in the case as another source of payment by claiming a physician-patient relationship existed, thus establishing he had a legal duty to ensure the care was within the accepted standard.